Uptake of novel systemic therapy: Real world patterns among adults with advanced non-small cell lung cancer.

ABSTRACT:

Introduction/background

Systemic treatment for advanced non-small cell lung cancer (NSCLC) is shifting from platinum-based chemotherapy to immunotherapy and targeted therapies associated with improved survival in clinical trials. As new therapies are approved for use, examining variations in use for treating patients in community practice can generate additional evidence as to the magnitude of their benefit.

Patients and methods

We identified 1,442 patients diagnosed with de novo stage IV NSCLC between 3/1/2012 and 12/31/2020. Patient characteristics and treatment patterns are described overall and by type of first- and second-line systemic therapy received. Prevalence ratios estimate the association of patient and tumor characteristics with receipt of first-line therapy.

SUBMITTER: Carroll NM 

PROVIDER: S-EPMC10528526 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature